Abetimus clinical trials
How each study uses abetimus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- abetimus sodium (LJP 394)
- 3
Studies by the year they started
2 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
La Jolla Pharmaceutical Company (3)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses abetimus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of LJP 394 (Abetimus Sodium) in Lupus PatientsWithdrawnPhase 2La Jolla Pharmaceutical CompanyNCT00390091Written as abetimus sodium (LJP 394)
- Study of LJP 394 in Lupus Patients With History of Renal DiseaseTerminatedPhase 3La Jolla Pharmaceutical CompanyNCT00089804Written as abetimus sodium (LJP 394)
- Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney DiseaseCompletedPhase 3La Jolla Pharmaceutical CompanyNCT00035308Written as Abetimus sodium (LJP 394)
Codes
What other systems call abetimus · ClinicalTrials.gg INT003853
- MeSH (NLM) C094104abetimusConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P3UVQ22SHKABETIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 1311600One source FDA
- Wikidata Q4667244abetimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174830AbetimusOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C094104 | abetimus | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P3UVQ22SHK | ABETIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1311600 | — | One source FDA |
| Wikidata | Q4667244 | abetimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174830 | Abetimus | One source FDA |
Also registered as abetimus sodium (UNII F5Y7739G6U · RxNorm 1311599).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.